Google
TLPH — TALPHERA INC. (Healthcare >> Drug Manufacturers - Specialty & Generic)
TLPH FAQ
What is TLPH's ROE?
TALPHERA INC. reports a Return on Equity (ROE) of -77.13%.
What is TLPH's dividend yield?
TALPHERA INC. offers a dividend yield of 0.00%.
What is TLPH's Deepscope Quality Score?
Deepscope rates TLPH's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TLPH?
Deepscope's AI Timing Score for TLPH is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TLPH belong to?
TALPHERA INC. is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 0.78
Price
-0.03
(-3.13%)
Day Change
|
|
|---|
TLPH, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.78 |
| PBV / Sector |
2.15 / 2.76
|
| Earning Per Share | -0.28 |
| PE / Sector |
N/A / 23.64
|
| PEG or PE/Growth / Sector |
N/A / 0.13
|
| Average 1M Daily Value |
0.12 M
GREAT
|
| Average 1W Daily Value |
0.11 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:44 |
| Symbol | TLPH |
| Name | TALPHERA INC. |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 51.90 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 39.71 / 9,835.56 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1850 Gateway Drive, San Mateo, CA, United States, 94404
Phone: 650 216 3500
Website: https://talphera.com
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
